Genentech Inc  (DNA) Trade Now »     Rate DNA  -  Discuss DNA  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

DNA: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Updated FDA Calendar of Decision Dates DNA

76%

-9.91% in 9 days Updated FDA Calendar of Decision Dates The accompanying table of FDA decision dates is updated to include the following: 1) XenoPort (XNPT) withdrew its NDA for restless leg syndrome drug Solzira for what appears to be a minor, administrative delay to reformat some trial data at the agency's request which will also delay $23M in milestone payments from partner GlaxoSmithKline (GSK); 2) Discovery Labs (DSCO) Surfaxin NDA will undergo a Class II review with a decision deadline pushed out to 4/17/09; 3) Genentech (DNA) filed for accelerated approval of Avastin as a s ... Continue reading »

Market Notes: Monday 10-November DNA

76%

-6.22% in 3 days (closed on 11/13/08) Stock Market News: Monday 10-November Biotech Mega-Deal Roche (RHHBY) has affirmed its intentions of buying the remaining 44% of Genentech (DNA) that it does not already own for $43.7B or $89 per share, which DNA rejected earlier this summer as undervaluing the company. A Paradigm Shift for Statin Drugs AstraZeneca reported results from a large-scale clinical trial dubbed JUPITER, demonstrating that its cholesterol-lowering statin drug Crestor caused a significant decrease in the incidence of cardiovascular events (e.g. heart attacks, strokes, angioplas ... Continue reading »

Healthcare ETFs Outpace the Market DNA

76%

+1.81% in 9 days (closed on 11/10/08) Healthcare ETFs Outpace the Market The accompanying table presents an analysis and statistics for the 28 healthcare ETFs listed at the Yahoo! Finance ETF Center. As a group, the healthcare ETFs outpaced the overall market in the past year by more than 10%, posting an average loss of 26.5% compared to a loss of 37.4% for the S&P 500 SPDR ETF (SPY). The best performing healthcare ETF was the Biotech HOLDRs (BBH), thanks to a buyout bid for top holding Genetech (DNA) and solid earnings results this year for the number two position, Amgen (AMGN). The top three ... Continue reading »

Amgen Exceeds Expectations, Again DNA

76%

+1.13% in 10 days (closed on 11/01/08) Amgen Exceeds Expectations, Again Shares of Amgen (AMGN) have moved into the green in after-hours trading following a late-day Wall Street sell-off that had the Dow tanking by over 500 points. As I wrote earlier today , Amgen was able to both exceed profit and sales expectations for 3Q08 and raise its full-year profit guidance as it had done three months ago when reporting 2Q08 results. Even with the current pop in after-hours to around $54 per share, Amgen is only trading at a PE of 12X on the mid-point of its 2008 profit guidance of $4.45 to $4.55 per share.Amgen poste ... Continue reading »

A Defensive Growth Stock Index DNA

76%

-2.64% in 2 days (closed on 10/22/08) A Defensive Growth Stock Index The accompanying table presents the ETFI Highly Defensive PerformIdex, which is structured as a market cap weighted, defensive growth index of 30 companies based in either the United States or Canada with the largest market capitalizations from each industry group (A-J) as specified below: (A) Grocery Stores (1) (B) Consumer Staples (10) – Non-Food (2), Food (4), Tobacco (1), Alcoholic Beverages (1), and Non-Alcoholic Beverages (2) (C) Health Benefit Providers (3) – Managed Healthcare (1), Supplemental Health (1), and ... Continue reading »

From the Blogosphere

Stock Market News: Monday 10-November

76%

Biotech Mega-Deal Roche (RHHBY) has affirmed its intentions of buying the remaining 44% of Genentech (DNA) that it does not already own for $43.7B or $89 per share, which DNA rejected earlier this summer as undervaluing the company. A Paradigm Shift for Statin Drugs AstraZeneca reported results from a large-scale clinical trial dubbed JUPITER, demonstrating that its cholesterol-lowering statin drug Crestor caused a significant decrease in the incidence of cardiovascular events (e.g. heart attacks, strokes, angioplasty procedures) and total mortality rates among individuals with low to normal c... Continue reading »

Who Will Replace GM in the Dow?

76%

While the fate of General Motors (GM) as a company is being debated by legislators and others, investors would agree that GM will be removed from the Dow Jones Industrial Average as the common stock faces the likely prospect of heading to zero despite efforts for a bailout of workers and suppliers. Some companies to consider as a replacement for GM include: Abbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. Over the past decade, ABT has consistently raised its divi... Continue reading »

Updated FDA Calendar of Decision Dates

76%

The accompanying table of FDA decision dates is updated to include the following: 1) XenoPort (XNPT) withdrew its NDA for restless leg syndrome drug Solzira for what appears to be a minor, administrative delay to reformat some trial data at the agency's request which will also delay $23M in milestone payments from partner GlaxoSmithKline (GSK); 2) Discovery Labs (DSCO) Surfaxin NDA will undergo a Class II review with a decision deadline pushed out to 4/17/09; 3) Genentech (DNA) filed for accelerated approval of Avastin as a secondary treatment of brain cancer (glioblastoma) based on positiv... Continue reading »

Updated FDA Calendar of Decision Dates

76%

The accompanying table of FDA decision dates is updated to include the following: 1) XenoPort (XNPT) withdrew its NDA for restless leg syndrome drug Solzira for what appears to be a minor, administrative delay to reformat some trial data at the agency's request which will also delay $23M in milestone payments from partner GlaxoSmithKline (GSK); 2) Discovery Labs (DSCO) Surfaxin NDA will undergo a Class II review with a decision deadline pushed out to 4/17/09; 3) Genentech (DNA) filed for accelerated approval of Avastin as a secondary treatment of brain cancer (glioblastoma) based on positiv... Continue reading »

Who Will Replace GM in the Dow?

76%

While the fate of General Motors (GM) as a company is being debated by legislators and others, investors would agree that GM will be removed from the Dow Jones Industrial Average as the common stock faces the likely prospect of heading to zero despite efforts for a bailout of workers and suppliers. Some companies to consider as a replacement for GM include: Abbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. Over the past decade, ABT has consistently raised its divi... Continue reading »

Trade DNA Now
and Get 30 Free Trades »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.